

HIGHLIGHTS IN THIS ISSUE

- Former UCLA Cardiovascular Scientist Pays it Forward.....p. 2
- Save the Date.....p. 3
- Building a Cardio-Oncology Clinic at UCLA.....p. 3-4
- Rising Stars in Cardiac Imaging.....p. 5
- In the Spotlight: Dr. Nicoletta Savalli.....p. 5
- A New Option for AF Patients.....p. 6
- Naturally Dissolving Stent Improves Cardiac Care.....p. 6
- Planting the Seeds.....p. 7

A FEW WORDS FROM LEADERSHIP

Dear Friends:

Since our initial *Heart to Heart* newsletter in 2016, many exciting advancements have occurred in cardiovascular medicine, research, and teaching at UCLA. Notable among these are:

- The inaugural Cardiovascular Theme Symposium, held on the UCLA campus in September 2016, which brought together leaders from across the country
- Seed grant funding to support new cardiovascular research and innovation on campus
- Outreach events to engage the broader Los Angeles community

We invite you to explore these and other highlights from the past few months in this issue. Several exciting developments to report from 2017 include the scheduling of the second Cardiovascular Theme Symposium, headlined with a lecture by Steven Houser, Ph.D., Professor and Chair of Physiology at Temple University and President of the American Heart Association.




Yibin Wang, Ph.D.
Cardiovascular Theme Chair
Professor of Anesthesiology,
Physiology, and Medicine



James N. Weiss, M.D.
Cardiovascular Theme Co-Chair
Chizuko and Nobuyuki Kawata
Chair in Cardiology

UCLA INAUGURAL CARDIOVASCULAR SYMPOSIUM FEATURES GLOBAL CARDIOVASCULAR LEADERS




Nearly 400 scientists, clinicians, and trainees attended the inaugural Cardiovascular Theme Symposium on September 2, 2016. Held in the new UCLA Meyer & Renee Luskin Conference Center on the UCLA campus, the intensive, one-day symposium was the first scientific conference sponsored by the UCLA Cardiovascular Theme and included lectures from nine global leaders in the field of cardiovascular research and medicine.

Ninety-six graduate students, postdoctoral fellows, clinical residents, clinical fellows, project scientists and early-career faculty participated in a poster session during the symposium to present their research. Of the greater than 90 abstracts presented, seven participants received awards in the categories of graduate students and clinical/research fellows.

Organized by UCLA faculty members Reza Ardehali, M.D., Ph.D., and Luisa Iruela-Arispe, Ph.D., the event introduced the mission of the Cardiovascular Theme to attendees and included an overview of UCLA cardiovascular medicine and research.

The mission of the Cardiovascular Theme at UCLA is to pioneer discoveries to prevent, detect, and cure cardiovascular disease.

FORMER UCLA CARDIOVASCULAR SCIENTIST PAYS IT FORWARD



Dr. Glenn A. Langer

When Glenn A. Langer, M.D., retired as Director of the Cardiovascular Research Laboratory at UCLA, he founded the Partnership Scholars Program, which provides financial aid, mentoring, and cultural enrichment for promising students in underserved communities. UCLA's Thomas Vondriska, Ph.D., spoke with Dr. Langer about his work at UCLA and the scholarship program.

Dr. Thomas Vondriska: Can you tell me about your vision in the early days of the Cardiovascular Research Lab, or the so-called “Heart Lab” at UCLA?

Dr. Glenn Langer: We were the first of those laboratories investigating cardiac function at a very basic and primordial level—in other words, subcellular—to be established by the American Heart Association. That approach is still intact and, although it has changed, the idea still remains: What makes the heart tick?

Dr. V: The words “basic” and “primordial” make me wonder what your thoughts are on the balance between fundamental and translational research.

Dr. L: There was a lot that was not understood at the time about literally what made the heart tick. We were a multidisciplinary laboratory. We had everything from physiology down to the chemical and subcellular level. The support from the local heart association was fundamental, and then later on with funding from the National Institutes of Health (NIH) we ended up with an annual budget in millions of dollars. With these resources, we were able to bring in young people, train them, and send them on their way into the academic world.

Dr. V: Can you share how you first got interested in myocardial calcium and why you thought it was important to understand its role in normal and diseased physiology?

Dr. L: Take calcium away in a beating heart and it stops, which indicated the fundamental role that it played, but at the time we came into the field it was really not understood in any way. Nobody really had the techniques. Through the invention of the essential new techniques, we were able to identify a critical link between excitation, the electrical signal in the heart, and the contraction. Subsequent studies then defined what linked those two fundamental processes together.

Dr. V: You founded the Partnership Scholars Program. Can you share some thoughts on your motivation for starting it?

Dr. L: I was born in 1928 and when I was about 8 years old my dad lost his job due to the Great Depression. He was out of work for more than three years. I know what it's like to not know where the next buck is coming from. Only through a totally random event did I get a college education, or a medical education. I went to university for undergraduate and then pre-med, but I had no idea how I was going to go to medical school. Scholarships for medical school at that time were few and far between. At a reception, a friend of mine happened to hear a distinguished gentleman, Charles Robertson, talking about a family that was looking for students who required funding to go to medical school. My friend told him about me, we met, and he supported all of my medical school education and postdoctoral training. That had a crucial impact on my life. I thought that I should be doing some payback and when I got to the stage where I had a few extra bucks, I thought of the Partnership Scholars Program. It is now in the 23rd year and 360 kids have graduated. These kids go on to receive support for college through other sources outside our program.

Dr. V: I read that you had personally supported more than 30 students with your own resources. How were you able to convince other people to see your vision about this need?

Dr. L: The donors realize that there is a real need here. We started it at Lennox Middle School and decided on the 7th grade, which turns out to be just the critical time. These students have their individual extracurricular activities structured to show them what a college education will provide for them and 92 percent of the students go on to four-year colleges. It's been extremely gratifying, it really works, and we now have a program in Northern California. It is a challenge to not only spread the word, but also to raise funds.

Dr. V: You also pair your students with mentors.

Dr. L: Yes, college educated, volunteer mentors, who are the crux of the program. We pay their expenses but they get a great deal of pleasure out of the program and they see that the time they invest is multiplied. Across the country there are millions of kids who could benefit from this program. We are taking a step at a time and it's better to try to do something than curse the darkness.

Dr. V: That's wonderful. I really appreciate your time, Dr. Langer.

Dr. L: I appreciate your taking the time and your interest. The more people who know about it the better. I'm glad to do something that helps make these opportunities possible for more kids.

SAVE THE DATE FOR THE NEXT CARDIOVASCULAR THEME SYMPOSIUM

Building on the success of its inaugural symposium, UCLA will present the next UCLA Cardiovascular Theme Symposium on September 25 and 26, 2017. Join cardiovascular experts from across the country, including keynote speaker Professor Steven R. Houser, Ph.D., President of the American Heart Association; Aruni Bhatnagar, Ph.D., University of Louisville; Robert Gerszten, M.D., Ph.D., Beth Israel Deaconess Medical Center/Harvard Medical School; Jeffery Molkentin, Ph.D., Cincinnati Children's Hospital; John Rogers, Ph.D., Northwestern University; Christine Albert, M.D., Brigham and Women's Hospital/Harvard Medical School; and Xander Wehrens, M.D., Ph.D., Baylor College of Medicine. Speakers from UCLA include, Marmar Vaseghi, M.D., Ph.D.; Tzung Hsiai, M.D., Ph.D.; and Kristina Bostrom, M.D., Ph.D.

UCLA WOMEN & PHILANTHROPY HOSTS HEART HEALTH SEMINAR

According to the American Heart Association, only 55 percent of women know that cardiovascular disease is the No. 1 cause of death among women. An even smaller percentage of women know the symptoms of heart disease or stroke. The UCLA Women's Cardiovascular Center and Barbra Streisand Heart Health Program are committed to community outreach to raise awareness and empower women to take charge of their heart health.

On March 9, UCLA Women & Philanthropy hosted an educational seminar on cardiovascular health at the Center Club Orange County in Costa Mesa. The event included presentations by UCLA cardiologists on four topics:

- The need for cardiovascular screenings
- Stress and heart disease
- Lifestyle and heart disease
- Current research in women's cardiovascular disease


Special guest Ann Meyers Drysdale, a 1978 UCLA graduate, Bruin athlete, and inductee into the Naismith Memorial Basketball Hall of Fame, who was ranked as one of the 10 greatest female athletes of all time by *Time Magazine*, spoke about how heart disease has affected her family.

Fourth in a series of conversations with UCLA women cardiologists, this was the first event held in Orange County. Cardiologists from the UCLA Women's Cardiovascular Center in Westwood, Karol E. Watson, M.D., Ph.D.; Tamara B. Horwich, M.D., M.S.; and Marcella Calfon Press, M.D., Ph.D., partnered with Reena Patel, M.D., of Redondo Beach Primary and Specialty Care Center, and Sheila Sahni, M.D., Interventional Cardiology Fellow at the David Geffen School of Medicine at UCLA. The presentation was followed by a reception with heart-healthy refreshments.



(From left): Ann Meyers Drysdale; Drs. Reena Patel, Tamara Horwich, and Sheila Sahni; volunteers Melissa Pugash and Tracy Isenberg; and Drs. Marcella Calfon Press and Karol Watson.

BUILDING A CARDIO-ONCOLOGY CLINIC AT UCLA



Dr. Eric Yang

With advances in cancer treatment resulting in significant increases in survival rates in cancer patients, the short- and long-term concerns of cancer treatment-induced cardiotoxicity have catalyzed a new multidisciplinary field: cardio-oncology. UCLA aims to be a leader in caring for the cardiovascular health of cancer patients at all stages of treatment: before, during, and after chemotherapy and radiation. "We

now know that many cancer therapies, while lifesaving, may potentially have short-and long-term consequences for the patient's heart health," said Eric Yang, M.D., who, along with colleagues in cardiology and hematology/oncology at Ronald Reagan UCLA Medical Center, is developing the UCLA Cardio-Oncology Clinic.

"Our primary goal is to allow the cancer patient to undergo their needed treatments, while identifying any potential cardiac risks, either preexisting or acquired during their treatment," Dr. Yang said. "By monitoring their cardiovascular symptoms proactively we can work with our oncology colleagues to provide the most optimal multifaceted care with cardioprotective interventions that will allow them to complete their cancer treatments with minimal risk to the cardiovascular system. Hopefully, this will confer long-term benefits as well."

Dr. Yang became involved in this field when he began seeing patients referred by Jacqueline Casillas, M.D. (UCLA pediatric hematology/oncology); Patricia Ganz, M.D. (UCLA adult hematology/oncology); and Amy Jacobson, R.N., N.P., of the UCLA-LIVESTRONG Survivorship Center of Excellence. A major objective of the program is to increase awareness among physicians within the spectrum *(Continued on page 4)*

BUILDING A CARDIO-ONCOLOGY CLINIC AT UCLA (CONT.)


of cardiology and hematology/oncology about cardiac risks related to each patient’s treatment plan. Since many evaluations are urgently required in order to proceed with or continue treatment, same-day cardiology evaluations have been offered, including in UCLA Health clinics throughout Greater Los Angeles.

“Whenever there is a new cancer drug, there is a new possibility for unforeseen cardiovascular side effects,” said Dr. Yang. “Our mission is to understand these effects so we can better treat them, and also provide psychological support to the patients so they understand why there is a need to balance cancer care with cardiac care. On a larger scale, we are hoping to identify mechanistic links that tie cardiotoxicity with traditional forms of cardiovascular disease, such as heart failure, coronary artery disease, or peripheral vascular disease. Currently, while there has been an explosion in literature within the cardio-oncology field, I personally feel that it is still at an observational phase, compared


to many other aspects of cardiovascular disease. We are working to transform the field from a reactionary science to a preventive one, which can foster invaluable collaborations between cardiology and oncology colleagues. This includes partnering with local and national institutions for improved data collection and information sharing, collaborating on translational and basic science research between the two fields, and investigating randomized control trials in cardiotoxicity surveillance and treatments.”

It is estimated that by 2026 there will be more than 20-million cancer survivors in the United States. “Some symptoms don’t manifest until a year or more after treatments have been completed,” said Dr. Yang. “Our goal is earlier detection and treatment, which will give the patient better quality of life and long-term outcomes.”

Cardio-oncology Clinic Visit Related to Cancer Treatment



Cardio-oncology Clinic Volume by Cancer Type



PULMONARY HYPERTENSION RESEARCH IN THE UCLA DIVISION OF MOLECULAR MEDICINE



Drs. Soban Umar and Mansoureh Eghbali

Pulmonary hypertension is an incurable disease affecting the lungs and the heart. This deadly disease affects women more than men and, for reasons largely unknown, the incidence of this disease is much higher in younger females. Over the years, Mansoureh Eghbali, Ph.D., Associate Professor of Anesthesiology and Medicine; and Soban Umar, M.D., Ph.D., Assistant Professor of Anesthesiology in the Division of Molecular Medicine of the


UCLA Department of Anesthesiology and Perioperative Medicine have investigated the basis for gender differences found in the development of pulmonary hypertension. Using state-of-the-art scientific models as well as human explant lung samples, they have researched the role the hormone estrogen and its receptors play in causing pulmonary hypertension. In collaboration with Abbas Ardehali, M.D., Director, UCLA Heart, Lung, and Heart-Lung Transplant Programs, they are currently investigating

the effects of sex chromosomes on the development of pulmonary hypertension using genetically modified scientific models. Dr. Umar recently received the prestigious American Thoracic Society Jerry Wojciechowski PH Proof of Concept Grant titled, “Y Chromosome Confers Protection Against Pulmonary Arterial Hypertension.” The long-term goals of their research are to unravel the mystery of the higher prevalence of pulmonary hypertension in young women and to lay the groundwork for a better understanding of the role of estrogens, androgens, and sex chromosomes in the lungs during the progression of pulmonary hypertension. Their research has translational potential and may result in novel therapeutic strategies for pulmonary hypertension. The work also has the potential to improve clinical outcomes for hundreds of thousands of patients in the U.S. and around the world who are annually afflicted with pulmonary hypertension.



Dr. Abbas Ardehali

RISING STARS IN CARDIAC IMAGING AT THE UCLA/VA GREATER LOS ANGELES HEALTHCARE SYSTEM



Kim-Lien Nguyen, M.D., is an Assistant Clinical Professor of Medicine at the UCLA/VA Greater Los Angeles Healthcare System. Dr. Nguyen received her medical doctorate from the David Geffen School of Medicine at UCLA and served as a housestaff in the Longcope Firm of the Osler Medical Training Program at Johns Hopkins Medicine.

Following completion of her general cardiology fellowship at UCLA, she was recruited to the National Heart, Lung, and Blood Institute as a fellow in the Advanced Cardiovascular Imaging Section. Dr. Nguyen joined the UCLA faculty in 2013 with clinical expertise in cardiovascular imaging (MRI, echo, CT, nuclear cardiology). In collaboration with Professor J. Paul Finn, M.D., and Professor Peng Hu, Ph.D., from the Department of Radiological Sciences at the David Geffen School of Medicine at UCLA, Dr. Nguyen focuses her research on the use of ferumoxytol for diagnostic MRI. Her projects are currently funded by a UCLA Clinical and Translational Science Institute award, and she is a co-investigator on an NIH-funded project to study HIV cardiomyopathy.



René R. Sevag Packard, M.D., Ph.D., is an Assistant Professor of Medicine at the UCLA/VA Greater Los Angeles Healthcare System. Dr. Packard graduated from the Conservatoire de musique de Genève as a concert pianist and violin virtuoso, and received his B.S. degree (*summa cum laude*) from the Collège Voltaire in Switzerland.

After earning his medical degree from the Faculty of Medicine at the University of Geneva, Switzerland, and completing vascular biology training in the laboratory of Peter Libby, M.D., at Brigham and Women's Hospital/Harvard Medical School, Dr. Packard was recruited to the UCLA Specialty Training and Advanced Research Program. His clinical expertise focuses on nuclear cardiology, echocardiogram, and computed tomography, and his research interest centers on advanced optics (laser light-sheet imaging) to study a zebrafish model of chemotherapy-induced cardiomyopathy. Dr. Packard is the recipient of an American Heart Association Scientist Development Grant (2016). In collaboration with the UCLA Cardiovascular Research Laboratory (Dr. James Weiss and Thao Nguyen, M.D., Ph.D.), he is a co-investigator on an NIH R01 project to assess electromechanical coupling of cardiac injury and repair.



Juhyun Lee, Ph.D., is a postdoctoral fellow in the UCLA Cardiovascular Engineering and Light-Sheet Imaging Laboratory.

Dr. Lee earned his B.S. in Bioengineering/Biomechanics at the University of Utah, an M.S. in Biomedical Engineering at the University of Southern California in 2012, and his Ph.D. in Bioengineering at UCLA in 2016.

Dr. Lee was awarded an American Heart Association Predoctoral Fellowship (2014-2016), and in 2016 he received the Harry M. Showman Prize as a top graduate student from the UCLA Henry Samueli School of Engineering and Applied Science. His research focuses on developing laser light-sheet imaging and post-imaging signal processing. Dr. Lee's contribution to elucidating developmental cardiomechanics has resulted in a first-author publication in the *Journal of Clinical Investigation* in 2016.

These next-generation physicians and scientists are spearheading discoveries in the cardiovascular imaging program at the UCLA/VA Greater Los Angeles Healthcare System.



IN THE SPOTLIGHT

Nicoletta Savalli, Ph.D., a trainee in the lab of Professor Riccardo Olcese, Ph.D., in the UCLA Department of Anesthesiology and Perioperative Medicine, received the 2017 postdoctoral Paul F. Cranefield Award in recognition of excellence in physiology. She will accept her award at the Society of General Physiologists/*Journal of General Physiology* mixer event during the 2017 Biophysical Society meeting in New Orleans. The work of Drs. Olcese and Savalli and their team was published in the *Journal of General Physiology*.


A NEW OPTION FOR AF PATIENTS



Dr. Eric Buch

The American Heart Association estimates that 2.7 million Americans live with atrial fibrillation (AF), also known as irregular heartbeat or arrhythmia. AF can lead to blood clots, stroke, heart failure, and other heart-related complications. Left untreated, AF doubles the risk of heart-related deaths and is associated with a five-fold increased risk for stroke. AF is a serious condition, the severity of which is affected by other underlying medical issues a person might have. UCLA now offers a new treatment option for patients with AF. According to Eric Buch, M.D., and Michael S. Lee, M.D., the Watchman device closes the left atrial appendage, which is the source of most blood clots that cause stroke in patients with AF. The result is a stroke risk that is similar to the blood-thinning drug warfarin, but without the need for long-term anticoagulation

medicine. Watchman is delivered by catheter via the femoral vein, without surgical incisions. The procedure typically takes 60-90 minutes and patients stay in the hospital for 24 hours. Warfarin is required for 45 days after implant, but 92 percent of patients stop at 45 days and 99 percent stop within one year of implant. The device is approved in 70 countries and more than 20,000 implants have been performed to date. Candidates for the Watchman device are AF patients who:



Dr. Michael S. Lee

- Are at increased stroke risk
- Can take warfarin short-term and aspirin long-term
- Seek a non-pharmacological alternative to permanent anticoagulation

NATURALLY DISSOLVING STENT IMPROVES CARDIAC CARE




From left: Tom Keep, Cath Lab technician; Dr. Gopi Manthripragada; and Carla Hatcher, Cath Lab nurse.

The use of a stent is an important part of cardiovascular treatment. Inserted into a clogged coronary artery, a stent helps keep the artery open and allows the blood to flow more freely, thus reducing the chance of a heart attack. Traditional stents are made of metal and are permanent implants that restrict vessel motion for the life of the person treated.

Employing a revolutionary technology, UCLA cardiologists William Suh, M.D.; Ravi Dave, M.D.; and Gopi Manthripragada, M.D., now use the Absorb GT1 bioresorbable vascular scaffold, a fully dissolving stent that is the first-of-its-kind, FDA-approved

medical device commercially available for the treatment of coronary artery disease.

Absorb, placed into the artery on a balloon at the end of a thin flexible tube, is expanded by inflating the balloon, which pushes the plaque against the artery wall to enable greater blood flow. The balloon is removed, leaving Absorb to slowly release medication to the diseased area. With blood flow restored, Absorb begins dissolving. Over time, Absorb dissolves into the blood vessel, which can remain open without support. The stent improves the inner space of the artery, restores blood flow, and enables movement of the treated vessel. The stent dissolves except for two pairs of tiny metallic markers that remain in the artery to enable a physician to see where the device was placed.



Stent photo courtesy of Abbott.

PLANTING THE SEEDS

Philanthropic Contributions Play an Indispensable Role in Fueling New Discoveries

Seed grants fund studies that promise to advance the understanding of biological processes and human disease, leading to novel strategies to improve human health. These studies often lead to larger grants from the NIH or other funding agencies or foundations, which further these vital investigations. Recent seed grantees include:




- **Jeff Abramson, Ph.D.:** Membrane transport proteins are responsible for many critical biological functions. He will use this grant to further his work with the voltage dependent anion channel, which is the most abundant protein of the outer mitochondrial membrane and is a potential target for cardiac protection.



- **Jessica Wang, M.D., Ph.D.:** Using a systems genetic approach to study the role of genetic variation in cardiovascular disease, her work has led to the identification of several candidate genes for cardiac remodeling. Her pilot study will advance investigations into genetic determinants of cardiac fibrosis.



- **Jason Hinman, M.D., Ph.D.:** His project will study the kinetics and fluid dynamics of cerebral microvascular occlusion and will utilize microfluidic devices to better predict microvascular events in patients.



- **Zhilin Qu, Ph.D.:** The objective of his project is to leverage advanced high-speed computing methods to develop a population-based approach that models the genetic diversity of human populations as a novel platform for anti-arrhythmic drug discovery and drug safety testing.

ENGAGING THE COMMUNITY



From left: Drs. Rose Marie Robertson; Yibin Wang; and Ravi Dave, UCLA Professor of Medicine and President of the Los Angeles Division of the AHA.

On February 8, 2017, UCLA and the American Heart Association (AHA) presented a joint scientific evening titled, “Heart Heroes: Advancements in Cardiovascular Research.” Held at the UCLA Center for Health Sciences (CHS), the evening included presentations by Rose Marie Robertson, M.D., F.A.H.A., AHA Chief Science and Medical Officer; Kalyanam Shivkumar, M.D., Ph.D., Professor of Medicine and Radiology and Director of the UCLA Cardiac Arrhythmia Center in the David Geffen School of Medicine at UCLA; and Dr. Yibin Wang, Cardiovascular Theme Chair. Guests also enjoyed a tour of the state-of-the-art lab space in CHS and appetizers.

Demonstrating the strong partnership between the AHA and UCLA, the AHA presented members of the UCLA Cardiovascular Theme with a check representing the total funding in peer-reviewed grant dollars from the AHA to UCLA cardiovascular investigators in 2016. The AHA has a long-standing commitment to supporting the most meritorious and impactful cardiovascular science in the forms of research grants and young investigator fellowships. UCLA, a national leader in cardiovascular medicine and research, has benefited from AHA funding since 1957.

DISTINGUISHED LECTURESHIPS AT UCLA

Symposia at UCLA this year featuring distinguished cardiovascular lecturers include the following:

UPCOMING EVENTS:

April 17: Srinivasa Reddy, Ph.D., UCLA

May 15: Third Biennial Los Angeles Cardiovascular Symposium

May 22: Rene Packard, M.D., Ph.D., UCLA

June 5: Gentian Lluri, M.D., Ph.D., UCLA

August 26: SECOND ANNUAL UCLA/SVS SYMPOSIUM: A Comprehensive Review and Update of What's New in Vascular and Endovascular Surgery

PAST EVENTS:

April 7: Anthony Rosenzweig, M.D., Massachusetts General Hospital

April 3: Jalees Rehman, M.D., University of Illinois College of Medicine

March 27: Raj Kishore, Ph.D., Lewis Katz School of Medicine at Temple University

March 13: Hesham Sadek, M.D., Ph.D., University of Texas Southwestern Medical Center

March 6: Julia Mack, Ph.D., UCLA

March 3-4: Third UCLA Autonomic Nervous System Control of the Heart in Health and Disease Symposium

February 27: Cooperative Gating of Calcium Channels in Muscle; Luis Fernando Santana, Ph.D., University of California, Davis

February 6: Vidu Garg, M.D., Nationwide Children's Hospital

January 13: Eric Peterson, M.D., Duke Clinical Research Institute

PUBLICATION HIGHLIGHTS BY CARDIOVASCULAR THEME INVESTIGATORS

- **Novel insights into cardiac calcification**, *Cell Stem Cell*, by Drs. I.C. Pillai, S. Li, M. Romay, L. Lam, Y. Lu, J. Huang, N. Dillard, M. Zemanova, L. Rubbi, Y. Wang, J. Lee, M. Xia, O. Liang, Y.H. Xie, M. Pellegrini, A.J. Lusic, A. Deb.
- **Population studies of heart failure incidence**, *Journal of Cardiac Failure*, by Drs. R.C. Chester, J.A. Gornbein, W.G. Hundley, P. Srikanthan, K.E. Watson, T. Horwich.
- **Health impacts of e-cigarettes**, *Journal of the American Medical Association Cardiology*, by Drs. R.S. Moheimani, M. Bhetraratana, F. Yin, K.M. Peters, J. Gornbein, J.A. Araujo, H.R. Middlekauff.
- **Treatment of cardiac arrhythmias**, *HeartRhythm*, by Drs. J.N. Weiss, Z. Qu, K. Shivkumar.
- **Therapeutic management of cholesterol levels**, *Journal of Lipid Research*, by Drs. D. Meriwether, D. Sulaiman, A. Wagner, V. Grijalva, I. Kaji, K.J. Williams, L. Yu, S. Fogelman, C. Volpe, S.J. Bensinger, G.M. Anantharamaiah, I. Shechter, A.M. Fogelman, S.T. Reddy.
- **Big data in research and medicine**, *Circulation*, by Drs. E. Lau, K.E. Watson, P. Ping.



CONGRATULATIONS TO UCLA'S SUPER DOCTORS

The following UCLA cardiologists made the Southern California Super Doctors 2017 list published in the January issue of *Los Angeles* magazine:

Jamil Aboulhosn
Noel Boyle
Eric Buch
Donald Cheng

Ravi Dave
Gregg Fonarow
Tamara Horwich
James Lee

Jeannette Lin
Freny Modi
Kalyanam Shivkumar
William Suh

Gabriel Vorobiof
Karol Watson
James Weiss

We encourage your feedback and inquiries about cardiovascular research, medicine, and education at UCLA.

FOR MORE INFORMATION ABOUT THE UCLA CARDIOVASCULAR THEME, PLEASE CONTACT:

Yibin Wang, Ph.D., UCLA Cardiovascular Theme Chair
(310) 206-5197 ■ yibinwang@mednet.ucla.edu

TO FIND OUT HOW YOU CAN SUPPORT UCLA CARDIOVASCULAR THEME RESEARCH AND TRAINING, PLEASE CONTACT:

Gina Weitzel, Senior Executive Director, Health Sciences Development
(310) 267-2112 ■ gweitzel@support.ucla.edu

Visit us at medschool.ucla.edu/cardiovascular



David Geffen
School of Medicine